ACS applied materials & interfaces · 2026
Charge-Mixed Nanogels for siRNA Delivery: Concurrent Optimization of Efficacy and Safety via Structure-Activity Relationships.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Yifan, Fang Jingying, Qiu Yuening, Yu Yilei, Du Fan, Cohen Stuart Martien A, Wang Junyou, Gao Rui
Аннотация
Cationic nanogels are efficient polymeric vectors for siRNA delivery but often raise toxicity concerns. To address this efficacy-toxicity trade-off, we present a charge-mixed nanogel platform that reconciles high delivery potency with excellent biocompatibility. Specifically, a library of cationic nanogels was synthesized with precise control over charge composition, size, and cross-linking degree, enabling systematic investigation of their effects on delivery performance and toxicity. Our findings reveal that delivery efficiency is cooperatively modulated by charge, size, and cross-linking degree, whereas toxicity reduction is primarily achieved by diluting the positive charge density through incorporation of anionic units. The established structure-activity relationship identified an optimal formulation comprising 80% cationic and 20% anionic monomers, with a hydrodynamic radius of approximately 83 nm and a cross-linking degree of 20% using a disulfide-based cross-linker. This design enables intracellular glutathione-responsive dissociation and efficient siRNA release. The engineered charge-mixed nanogels demonstrate potent gene silencing (83.0%) and antitumor efficacy (84.3%), alongside notably reduced cellular and systemic toxicity. Collectively, this work provides rational design principles for cationic nanocarriers and establishes a promising vector platform that effectively overcomes the efficacy-toxicity dilemma for advanced siRNA therapeutics.